| HAIR GROWTH | PEER-REVIEW The use of PRP for applications


in hair-loss is far from being minor. In the future, the authors hope to


improve the protocol and show that PRP also has a preventive effect on hair disorders.


evaluations are available. Nevertheless, obvious improvements can be seen (Figure 7).


Discussion In the authors’ evaluation, other than objective measurements, the subjective appreciation of patients is evaluated. There is a large chasm between objective measures and patient feelings; for example, the patient may feel satisfied with a small increase (10%), but dissatisfied with a significant result (40%). With regard to the standardisation of photography,


many factors must considered, including colour, length, hairdressing, and lighting. For these reasons, to get suitable results, an objective parameter is essential (i.e. the phototrichogram). Further guidelines for effective analysis are those tools which allow the authors to obtain the best phototrichogram possible (e.g. tattoo points, short cut, and dyeing solution). Most authors also agree that 50 patients is a minimum requirement to obtain efficient statistic results. Once the efficacy of PRP for hair-loss is demonstrated,


it would be interesting to compare the impact of different factors in future studies. For example, with or without dermaroller, with or without activation, or different volumes, as well as other hair pathologies, such as alopecia areata and telogen effluvium. Those explorations are very important regarding the


poor panel of treatments at our disposal almost for some of them which are disputed for long last using. PRP protocol can be an alternative solution.


Conclusions The use of PRP for applications in hair-loss is far from being minor. In the future, the authors hope to improve


References


1. Bouhanna P. Multifactorial classification of male and female androgenetic alopecia. Dermatol Surg 2000; 26(6): 555–61


2. Bouhanna P. The phototrichogram and a macrophotographic study of the scalp. Bioengineering and the Skin 1985; 1(3): 265


3. Amgar G, Bonnet C, Butnaru A, Herault-Bardin F. Using objective criteria to evaluate cosmetic effects of platelet rich plasma. PRIME 2011; 1(6): 31–41


4. Sclafani AP, McCormick SA. Induction of dermal collagenesis, angiogenesis, and adipogenesis in human skin by injection of platelet-rich fibrin matrix. Arch Facial Plast Surg 2012; 14(2): 132–6


5. Takakura N, Yoshida H, Kunisada T, Nishikawa S, Nishikawa SI. Involvement of platelet-derived growth factor receptor-alpha in hair canal formation. J Invest Dermatol 1996; 107(5): 770–7


6. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF- mediated angiogenesis. J Clin Invest 2001; 107(4): 409–17


7. Rinaldi F, Sorbellini E, Bezzola P. The role of up-stimulation of growth factors in hair transplantation: improve the revascularization of transplanted hair growth mediated by angiogenesis. Forum 2007; 2


8. Sharov A, Tobin DJ, Sharova TJ, Atoyon R, Botchkarev VA. Changes in different melanocyte populations during hair follicle involution. J Invest Dermatol 2005; 125(6): 1259–67


9. Li M, Marubayashi A, Nakaya Y, Fukui K, Arase S. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol 2001; 117(6): 1594–600


10. Mak KK, Kingston SY. Epidermal growth factor as a biologic switch in hair growth cycle. J Biol Chem 2003; 278(28): 26120–6


11. Rosenquist TA, Martin GR. Fibroblast growth factor signalling in the hair growth cycle: expression of the fibroblast-growth factor receptor and ligand genes in the


murine hair follicle. Dev Dyn 1996; 205(4): 379–86


12. Weger N, Schlake T. Igf-I signalling controls the hair growth cycle and the differentiation of hair shafts. J Invest Dermatol 2005; 125(5): 873–82


13. Mak KK, Kingston SY. A transgenic mouse model to study the role of epidermal growthfactor (EGF) in hair and skin development. Hong Kong: University of Hong Kong, 2002. http://tinyurl.com/ncubclj (accessed 22 May 2013)


14. Peters EMJ, Paus R, Klapp BF, Arck PC. L6 neuroimmunological hair growth control is stress-sensitive: an old paradigm revisited. http://tinyurl.com/ncltc3s (accessed 22 May 2013)


15. Sorbellini E. Trink A, Rinaldi F. Experimental clinical assessment of the use of platelet-rich plasma in dermatology and rationale for its use in the treatment of non-scarring alopecia. Presented at the 35th La Medicina Estetica 4 October 2011


16. Takikawa M, Nakamura S, Nakamura S et prime-journal.com | June 2013 ❚


al. Enhanced effect of platelet-rich plasma containing a new carrier on hair growth. Dermatol Surg 2011; 37(12): 1721–9


17. Greco J, Brandt R. The effects of autologus platelet rich plasma and various growth factors on non-transplanted miniaturized hair. Hair Transplant Forum International 2009; 18(2): 49–50


18. Uebel CO, da Silva JB, Cantarelli D, Martins P. The role of platelet plasma growth factors in male pattern baldness surgery. Plast Reconstr Surg 2006; 118(6): 1458–66


19. Greco J, Brandt R. Our Experience Utilizing Autologous Platelet Rich Plasma in all Phases of Hair Transplant Surgery. Hair Transplant Forum International 2007; 17(4): 131–2


20. Reese R. A single-blinded, randomized controlled study of the use of autologous platelet rich plasma PRP as a medium to reduce scalp hair transplant adverse effects. Hair Transplant Forum International 2008; 18(2): 51–2


Key points


■ The action of different growth factors on the hair follicle is quite complicated, but now well understood


■ Many publications confirm the efficacy of platelet-rich plasma (PRP) in hair disorders


■ In hair surgery and transplantation, PRP can improve the donor area and increase graft survival


■ PRP could be an alternative treatment for androgenic alopecia


the protocol and show that PRP also has a preventive effect on hair disorders. This method will not replace the hair graft, but may be useful to delay such treatment and provide betterresults. The authors hope that this article will encourage clinicians to use objective measurements for their evaluation, respecting the standard guidelines.


Declaration of interest None Figures 1, 5, 6 ©Amgar and Bouhanna, 2 Reproduced


with kind permission of Dr Kiyozawa, 3, 4, 7 ©Greco The Hair PRP study tubes used for the authors’ study


were produced by MyCells.


31


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84